Immunosuppressive therapy of childhood idiopathic nephrotic syndrome

Expert Opinion on Pharmacotherapy

Volumn 3, Issue 5, 2002, Pages 513-519

  Abeyagunawardena, A ^a   Brogan, Paul A ^a   Trompeter, R S ^a   Dillon, Matthew J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

End stage renal failure; Nephrotic syndrome; Steroid dependent; Steroid resistant; Steroid sensitive

Indexed keywords

ALKYLATING AGENT; ANTHELMINTIC AGENT; CHLORAMBUCIL; CHLORMETHINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOTOXIC AGENT; DEFLAZACORT; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; LEVAMISOLE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PREDNISONE; TACROLIMUS;

ACUTE DISEASE; ALOPECIA; BEHAVIOR DISORDER; BLOOD TOXICITY; CANCER RISK; CATARACT; CHILD; CHILDHOOD; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE CONTROL; DISEASE COURSE; DOSE RESPONSE; DRUG RESPONSE; DRUG SENSITIVITY; GASTROINTESTINAL SYMPTOM; GONADAL DISEASE; GROWTH DISORDER; HEMORRHAGIC CYSTITIS; HIRSUTISM; HUMAN; HYPERTENSION; HYPOVOLEMIA; IDIOPATHIC DISEASE; IMMUNOSUPPRESSIVE TREATMENT; INFERTILITY; KIDNEY FAILURE; LIVER TOXICITY; MENTAL DISEASE; MINIMAL CHANGE GLOMERULONEPHRITIS; NEPHROTIC SYNDROME; NEPHROTOXICITY; OBESITY; OPPORTUNISTIC INFECTION; PRESCRIPTION; RECURRENCE RISK; REMISSION; REVIEW; SURVIVAL TIME; THROMBOSIS; TREATMENT OUTCOME; VASCULITIS;

ADRENAL CORTEX HORMONES; CHILD; CHILD, PRESCHOOL; EXPERT TESTIMONY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; NEPHROTIC SYNDROME;

EID: 0036098470     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.3.5.513     Document Type: Review

References (62)

1. Consensus statement on management and audit potential for steroid responsive nephrotic syndrome
2. The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. A report of the International Study of Kidney Disease in Children
3. Treatment of nephrosis with predinosolone
4. ISKDC: Controlled trial of azathioprine in children with nephrotic syndrome
5. Long-term outcome for children with minimal change nephrotic syndrome
6. Long-term outlook of primary nephrotic syndrome
7. Conventional therapy for idiopathic nephrotic syndrome in children
8. Alternate-day versus intermittent prednisone in frequently relapsing nephrotic syndrome
9. Short versus standard prednisone therapy for initial treatment of idiopathic nephrotic syndrome in children
10. Corticosteroid therapy in nephrotic syndrome: A meta-analysis of randomised controlled trials
11. Management of minimal lesion glomerulonephritis: Evidence-based recommendations
12. Early identification of frequent relapsers among children with minimal change nephrotic syndrome. A report of the International Study of Kidney Disease in Children
13. Clinical implications from studies of HLA antigens in idiopathic nephrotic syndrome in children
14. Unfavorable course of minimal change nephrotic syndrome in children with intrauterine growth retardation
15. Influence of age at onset on the outcome of steroid-sensitive nephrotic syndrome
16. Nephrotic syndrome in children: A randomised controlled trial comparing two prednisone regimens in steroid-responsive patients who relapse early. A report of the International Study of Kidney Disease in Children
17. Low dose prednisolone in nephrotic syndrome
18. Long versus standard prednisone therapy for initial treatment of idiopathic nephrotic syndrome in children
19. Growth and endocrine function in steroid sensitive nephrotic syndrome
20. Normal growth of nephrotic children during long-term alternate day prednisone therapy
21. Pathogenesis of lipoid nephrosis: A disorder of T-cell function
22. Lymphocyte subpopulations, interleukin-2 and interleukin-2 receptor expression in childhood nephrotic syndrome
23. T cell subsets, interleukin-2 receptor expression and production of interleukin-2 in minimal change nephrotic syndrome
24. Primary and secondary abnormalities of T cell sub populations
25. Th1 and Th2 Cytokine mRNA Profiles in Childhood Nephrotic Syndrome: Evidence for Increased IL-13 mRNA Expression in Relapse
26. Management, complications and outcome of steroid sensitive nephrotic syndrome
27. Alternative treatment to corticosteroids in steroid sensitive idiopathic nephrotic syndrome
28. Immunosuppressive therapy in nephrotic syndrome in children
29. Minimal change nephrotic syndrome and cyclophosphamide
30. Controlled trial of cyclophosphamide in steroid-sensitive relapsing nephrotic syndrome in childhood
31. Idiopathic nephrotic syndrome of childhood: Cyclophosphamide induced conversion from steroid refractory to highly steroid sensitive disease
32. Cyclophosphamide treatment in steroid-sensitive nephrotic syndrome of childhood
33. Pattern of response to prednisone in idiopathic, minimal lesion nephrotic syndrome as a criterion in selecting patients for cyclophosphamide therapy
34. Cyclophosphamide treatment of steroid dependent nephrotic syndrome: Comparison with 8 week with 12 week course
35. Eight and 12 week courses of Cyclophosphamide in nephrotic syndrome
36. Comparative trial of 2 weeks and 8 weeks cyclcophosphamide in steroid-sensitive relapsing nephrotic syndrome of childhood
37. Gonadal function, testicular histology and meiosis following cyclophosphamide therapy in patients with nephrotic syndrome
38. Treatment of childhood steroid-resistant idiopathic nephrosis with a combination of cyclosporin and prednisone
39. Pulse cyclophosphamide therapy in frequently relapsing nephrotic syndrome
40. Chlorambucil treatment of frequently relapsing nephrotic syndrome
41. A meta-analysis of cytotoxic treatment for frequently relapsing nephrotic syndrome in children
42. Long-term cyclosporin A treatment of minimal-change nephrotic syndrome of childhood
43. Management of nephrotic syndrome in children
44. Lymphoma and cyclosporin
45. Malignant lymphoma in a renal transplant patient on cyclosporin A therapy
46. One-center experience with cyclosporin in refractory nephrotic syndrome in children
47. Nitrogen mustard therapy in idiopathic nephrotic syndrome of childhood
48. Vincristine and focal segmental sclerosis: Do we need a multi-centre trial?
49. Pilot trial of FK 506 in the management of steroid-resistant nephrotic syndrome
50. Remission of relapsing childhood nephrotic syndrome with mycophenolate mofetil
51. Treatment of steroid-resistant focal segmental glomerulosclerosis with pulse methylprednisolone and alkylating agents
52. Levamisole for corticosteroid-dependent nephrotic syndrome in childhood
53. Levamisole-induced vasculitis
54. Levamisole in steroid-sensitive nephrotic syndrome children with steroid-dependency and/or frequent relapses
55. Liver toxicity in a nephrotic patient treated with levamisole
56. Use of levamisole in maintaining remission in steroid-sensitive nephrotic syndrome in children
57. Protracted levamisole in children with frequent-relapse nephrotic syndrome
58. Infections in paediatric renal transplant recipients
59. Gonadal function in women treated with cyclophosphamide for childhood nephrotic syndrome: A long-term follow-up study
60. Sporadic FSGS due to mutation of podocin. Clinical picture and comparison with idiopathic FSGS
61. Mutations in NPHS2 is a prevalent cause of steroid-resistant nephrotic syndrome in Israeli-Arab children
62. Incidence, treatment and outcome of recurrent focal segmental glomerulosclerosis post transplantation in 42 allografts in children- a single-centre experience